This site is intended for healthcare professionals only
LoginRegister
Lupin Partners with TB Alliance to Advance Telacebec for TB, Leprosy and Buruli UlcerBioNTech, OncoC4 collaborate to co-develop and commercialize novel checkpoint antibody in multiple...
positive phase 3 trialConcert Pharma Deuruxolitinib significantly improves scalp hair regrowth in Alopecia areata, reveals...
USFDA nod to Caplin Steriles Rocuronium Bromide InjectionUSFDA nod to Caplin Steriles Rocuronium Bromide Injection
USFDA grants Orphan Drug Designation to Zyduss ZYIL1 for treatment of Cryopyrin Associated Periodic SyndromeUSFDA grants Orphan Drug Designation to Zydus's ZYIL1 for treatment of Cryopyrin Associated Periodic...
Lupin unveils Risperidone Long Acting Injectable in USLupin alliance partner Caplin Steriles bags USFDA okay for Thiamine Hydrochloride Injection
CDSCO issued show cause notice to 31 firms following concerns over e-pharmacies: MoS Health Bharati Pravin PawarCDSCO issued show cause notice to 31 firms following concerns over e-pharmacies: MoS Health Bharati...
How sleep health can shape well being of Indian population Ft Dr Sibasish DeyHow sleep health can shape well being of Indian population Ft Dr Sibasish Dey
Takeda declares positive results in Phase 2b Study of TAK-279 in people with moderate-to-severe Plaque PsoriasisTakeda declares positive results in Phase 2b Study of TAK-279 in people with moderate-to-severe...
Ayurveda group Vaidyaratnam plans to double revenue to Rs 500 crore, IPO by 2030Ayurveda group Vaidyaratnam plans to double revenue to Rs 500 crore, IPO by 2030
Chemists Body Warns of 55% Rise in Drug Abuse, Calls for Ban on 10-Minute Prescription Drug DeliveryE-Pharmacies operating against the laws in country, AIOCD lashes out at FICCI
XTANDI plus Leuprolide improves Metastasis-Free survival in men with non-metastatic prostate cancer: PfizerXTANDI plus Leuprolide improves Metastasis-Free survival in men with non-metastatic prostate cancer:...
CDSCO Panel approves Phase IV CT of Hetero-Trastuzumab marketed formulationCDSCO Panel approves Phase IV CT of Hetero-Trastuzumab marketed formulation
X